DeuterOncology is focused on the pre-clinical validation and development of DO-2, a novel MET and RAS pathway inhibitor sublicensed (worldwide rights outside of greater China) from OCTIMET Oncology NV and originally licensed from Janssen Pharmaceutica in 2017. DeuterOncology’s portfolio contains a sublicense to the all OCTIMET compounds, includes a clinical-stage MET kinase inhibitor that has been evaluated in both a monotherapy and combination therapy setting in cancer patients in Europe. DeuterOncology works together with a broad established network of collaborators across the world to try to bring new solutions to cancer patients
Employees: 1-10
Total raised: $6.12M
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | Newton Bio... | newtonbioc... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.01.2023 | Series A | $6.12M | - |
Mentions in press and media 2
| Date | Title | Description |
| 19.01.2023 | DeuterOncology Closes €5.65M Series A Financing Round | DeuterOncology, a Liege, Belgium-based clinical-stage drug development company, raised €5.65M in Series A funding. The round was led by Newton Biocapital, Noshaq and Investsud Tech. The company intends to use the funds to start the phase I ... |
| - | DeuterOncology | “Home | DeuterOncology NV” |